News

Three New Industry Members Join the Alliance


Three New Industry Members Join the Metastatic Breast Cancer Alliance

Over 40 leading public and private partners working together to improve the lives of people living with metastatic breast cancer

May 18, 2016: The Metastatic Breast Cancer Alliance (“the Alliance”) welcomes the addition in 2016 of three new industry members—MacroGenics, Genomic Health and R-Pharm US—to its advocacy-led effort to accelerate research progress and increase awareness about the disease and patient care.

Launched in 2013, the Alliance is the only breast cancer coalition in the U.S. focused 100 percent on metastatic breast cancer with an unparalleled collective of stakeholders supporting groundbreaking research, patient support and public education about metastatic breast cancer. The group comprises more than 40 members representing patient advocacy, industry, and private funding.

MacroGenics, Genomic Health, and R-Pharm US join seven other leading industry members—AstraZeneca, Celgene Corporation, Eisai, Genentech, Lilly Oncology, Novartis Oncology and Pfizer—all focused on innovative research projects and educational programs for people living with metastatic breast cancer.

Each year about 40,000 women and men will die of metastatic breast cancer. While treatable, metastatic breast cancer remains incurable.

“This statistic cannot be reduced by working alone,” stated Dr. Marc Hurlbert, Chair of the Alliance and Chief Mission Officer of the Breast Cancer Research Foundation. “The Alliance speaks in a unified voice to advance progress in scientific research, increase awareness about patient care and services, and educate the public about metastatic breast cancer. We welcome our newest members who will join our longstanding partners in bringing their expertise to the table and actively working together to accomplish our vision.”

According to Hurlbert, while there is much awareness of, and media attention on, early stage breast cancer, there must be a greater emphasis on metastatic breast cancer and how it differs from early stages. This will help give patients, their families, health care providers, researchers and health policy experts a better understanding of this advanced stage and the different treatment and quality of life needs of patients.

Since its 2014 landmark report, Changing the Landscape for People Living with Metastatic Breast Cancer, the Alliance has been actively working to close gaps for people living with metastatic breast cancer in research, clinical trials, quality of life, patient education and support services, and epidemiology. Its initiatives have included gathering more than 55 key opinion leader insights from research centers, pharmaceutical companies, the FDA and NCI on how to remove barriers to progress in research, creating a data visualization tool for clinical trials, piloting a prototype of a communication toolkit to improve conversations between health care professionals and patients, and developing public awareness campaigns.

For more information, visit mbcalliance.org and follow MBCA on Facebook (/mbcalliance), Twitter (@mbcalliance), and YouTube (MBCAllianceVideos).

Contact: Katherine Crawford-Gray, Director, MBC Alliance katherine@mbcalliance.org